DierenDokters has been acquired by VetPartners
DierenDokters, a leading group of fourteen veterinary clinics located across the Netherlands, has been acquired by VetPartners, a UK-based group of over 650 veterinary clinics and hospitals located across Europe. By partnering with VetPartners, DierenDokters welcomes a strong new shareholder that will help further enhance DierenDokters’ clinics’ service offering and allow the clinics to continue focusing on providing the best possible animal healthcare services.
Founded in 2004, DierenDokters offers a comprehensive range of primary animal care services, complemented by each clinic having its own specific focus on multiple and more complex veterinary conditions. By leveraging its strong branding and online presence, continuous compliance monitoring on standard of care, price monitoring and dedicated focus on customer communication, DierenDokters holds a strong position in the Dutch veterinary services market.
Established in October 2015, VetPartners, a portfolio company of European private equity firm BC Partners, is made up of some of the UK’s most respected and trusted small animal, equine, mixed and farm practices and production animal health businesses. The acquisition of DierenDokters enables VetPartners to expand into another European country, the Netherlands.
Oaklins’ team in the Netherlands acted as the exclusive M&A sell-side advisor to the shareholders of DierenDokters. This transaction emphasizes Oaklins’ strong track record and expertise in the healthcare clinics and consumer & retail sectors.
Jeroen Dreuw and Maico Boumans
Former shareholders and co-founders, DierenDokters
Talk to the deal team
Related deals
Medicija has acquired Saulės Šeimos Medicinos Centras
Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.
Learn moreQuimpharma has completed the divestiture of a product portfolio to Megalabs
Quimpharma has completed the divestiture of a product portfolio to Megalabs México.
Learn moreIXICO has completed a fundraising
IXICO plc, a specialist in AI-driven neuroimaging analytics, has completed a US$13.5 million gross capital raise. The funds will be used to support the company’s tech bio strategy, which will see IXICO partner its platform to maximize its potential.
Learn more